Cart contains    items
SEARCH

  |
  |  
  |  
  |  
  |  
  |  
 
Browse by molecule: [A]  [B]  [C]  [D]  [E]  [F]  [G]  [H]  [I]  [J]  [K]  [L]  [M]  [N]  [O]  [P]  [Q]  [R]  [S]  [T]  [U]  [V]  [W]  [X]  [Y]  [Z]  

Human Interferon-beta 1a Recombinant

IFN-beta

accession:  P01574
   Size A     5ug   $ 70
   Size B      20ug  $160
   Size C      1mg  $ 3500
Domain  :  Four Helix Cytokine Core
Gene  :  IFNB1A
Catalog no. :  RKP01574
Source:
Optimized DNA sequence encoding Human Interferon beta 1a  mature chain was expressed in Chinese Hamster Ovary Cells.

 
Molecular weight:

Recombinant human IFN-beta 1a, generated by the proteolytic removal of the signal peptide and propeptide, and has a calculated molecular mass of approximately 19 kDa. 

Recombinant Interferon beta is a disulfide-linked monomeric protein consisting of 166 amino acid residue subunits, and migrates due to glycosylation as an approximately 22 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE.


 
Purity:
>98%, as determined by SDS-PAGE and HPLC

 
Biological Activity:
The activity was determined by the viral resistance assay  of Human WISH cells was found to be in the range of  3x108 IU/mg.

 
Protein Sequence:
        10         20         30         40         50         60 
MTNKCLLQIA LLLCFSTTAL SMSYNLLGFL QRSSNFQCQK LLWQLNGRLE YCLKDRMNFD 

        70         80         90        100        110        120 
IPEEIKQLQQ FQKEDAALTI YEMLQNIFAI FRQDSSSTGW NETIVENLLA NVYHQINHLK 

       130        140        150        160        170        180 
TVLEEKLEKE DFTRGKLMSS LHLKRYYGRI LHYLKAKEYS HCAWTIVRVE ILRNFYFINR 


LTGYLRN 
(*)Complete precursor sequence shown, expressed chain highlighted
 
Endotoxin:
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).

 
Presentation:
Recombinant IFN-b 1a was lyophilized from a 0.2 μm filtered sodium acetate solution pH 4.8.

 
Reconstitution:
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.

 
Storage:
The lyophilized protein is stable for at least 2 years from date of receipt at -20° C.
Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity.

Avoid repeated freeze/thaw cycles.

 
Usage:
This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

 

 

Interferon beta 1a

IFN-beta is produced mainly by fibroblasts and some epithelial cell types. The synthesis of IFN-beta can be induced by common inducers of interferons including viruses, double-stranded RNA, and micro-organisms. It is induced also by some cytokines such as TNF and IL1. IFN-beta binds to the same receptor as IFN-alpha. IFN-beta is involved in the regulation of unspecific humoral immune responses and immune responses against viral infections. IFN-beta increases the expression of HLA class 1 antigens and blocks the expression of HLA class 2 antigens stimulated by IFN-gamma. IFN-beta stimulates the activity of NK-cells and hence also antibody-dependent cytotoxicity. IFN-beta shows antiproliferative activity against a number of cell lines established from solid tumors.

Related Publications:
randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis
Multiple Sclerosis, Aug 2009; 15: 965 - 976.
effect of statins on clinical and molecular responses to intramuscular interferon beta-1a
Neurology, Jun 2009; 72: 1989 - 1993.
efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria
Multiple Sclerosis, Jun 2009; 15: 728 - 734.
subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing—remitting multiple sclerosis: 2-year results from the cogimus study
Therapeutic Advances in Neurological Disorders, Mar 2009; 2: 67 - 77.
safety and immunogenicity of a new formulation of interferon β-1a (rebif® new formulation) in a phase iiib study in patients with relapsing multiple sclerosis: 96-week results
Multiple Sclerosis, Feb 2009; 15: 219 - 228.




by class:
Cytokines
Chemokines
Growth factors
CD markers
Viral Antigens
Other
by species:
Human
mouse
Rat
Antibodies:
Purified Polyclonal
Related Products:
product_icon_8.jpg Human Interferon-beta 1a Recombinant
 
 
 
Item name Size Quantity Price(USD) Remove
checkout
Cart Total $